CVMNYSE

CEL SCI CORP

Healthcare·Oncology·Phase 3·Vienna, VA, United States
OncologyImmunologyMusculoskeletal

CEL SCI CORP (CVM): 3 pipeline candidates · ~2 mo cash runway. Updated within the last hour.

6.4/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway0.4

1.6 months

Financial Health7.6

D/E 1.58 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider Signal9.5

3 buys · 0 sells (180d)

A transparent, data-derived signal for CEL SCI CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$14.6M

Cash

$1.9M

Quarterly Burn

$4.0M

Runway

1.6 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2026
Today~7 mo out
Catalyst within runway

Pipeline (3 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

36

Total value held

$2.8M

HolderSharesValue
vanguard capital management llc487,290$1.6M
geode capital management, llc85,311$274K
vanguard fiduciary trust co49,036$157K
blackrock, inc.43,261$139K
bank of america corp /de/40,997$132K
renaissance technologies llc35,890$115K
state street corp27,270$88K
xtx topco ltd22,556$72K
northern trust corp18,934$61K
commonwealth equity services, llc17,622$57K

Showing top 10 of 36 institutional holders of CEL SCI CORP. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Mr. Geert R. Kersten Esq.

Frequently asked questions

How many drug candidates are in CEL SCI CORP's pipeline?

CEL SCI CORP (CVM) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is CEL SCI CORP's lead drug candidate?

CEL SCI CORP's most advanced tracked candidate is L.E.A.P.S. (Preclinical) for Rheumatoid arthritis.

What is CEL SCI CORP's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, CEL SCI CORP has approximately 1.6 months of cash runway.

What is CEL SCI CORP's market capitalization?

CEL SCI CORP's market capitalization is approximately $14.6M.

Who is the CEO of CEL SCI CORP?

Mr. Geert R. Kersten Esq. is the chief executive officer of CEL SCI CORP (CVM).

Get the full picture on CEL SCI CORP

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.